+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Postexposure prophylaxis for HIV following sexual exposure



Postexposure prophylaxis for HIV following sexual exposure



Current Opinion in HIV and Aids 5(4): 322-326



Postexposure prophylaxis (PEP) has become an important part of combined approaches to the prevention of onward HIV transmission. As PEP becomes more widely available after sexual as well as occupational exposure, there are ongoing debates about cost-effectiveness and utility. Different regions have adopted different PEP strategies and the availability of new antiretroviral drugs and classes means that options for PEP regimens are increasing. This review is timely and of importance as it summarizes the evidence supporting current PEP usage and discusses potential future strategies for PEP prescribing. This review covers the biology and risk of HIV transmission and evidence supporting the use of PEP. It gives a summary of current guidelines including which agents to use, the potential for drug-drug interactions, possible alternative and potential novel PEP regimens, cost-effectiveness and research on effects of PEP on sexual behaviour. While reinforcing current practice around PEP prescribing, this review discusses possible future developments including the use of new antiretroviral drugs, new classes of antiretroviral drugs or novel strategies for PEP which are likely to be areas of research in the near future.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 055071121

Download citation: RISBibTeXText

PMID: 20543608

DOI: 10.1097/coh.0b013e32833a5e6c


Related references

Postexposure prophylaxis after sexual exposure to HIV. Current Opinion in Infectious Diseases 20(1): 39-46, 2007

Postexposure prophylaxis after sexual exposure to Hiv. Future Hiv Therapy 1(1): 35-47, 2007

What are the characteristics of, and clinical outcomes in men who have sex with men prescribed HIV postexposure prophylaxis following sexual exposure (PEPSE) at sexual health clinics in England?. Sexually Transmitted Infections 93(3): 207-213, 2017

Failure of postexposure prophylaxis after sexual exposure to HIV. Aids 15(3): 430, 2001

Postexposure prophylaxis for human immunodeficiency virus infection after sexual or injection drug use exposure: identification and characterization of the source of exposure. Journal of Infectious Diseases 184(12): 1608-1612, 2001

A model for communitywide delivery of postexposure prophylaxis after potential sexual exposure to HIV. Sexually Transmitted Diseases 34(5): 294-296, 2007

The Danish PEP registry: experience with the use of postexposure prophylaxis (PEP) following sexual exposure to HIV from 1998 to 2006. Sexually Transmitted Diseases 37(1): 49-52, 2010

The awareness of postexposure prophylaxis for HIV infection following sexual exposure in emergency departments in a regional HIV network. International Journal of Std and Aids 21(9): 636-637, 2010

Trends in HIV postexposure prophylaxis prescription and compliance after sexual exposure in Amsterdam, 2000-2004. Sexually Transmitted Diseases 34(5): 288-293, 2006

Use of postexposure prophylaxis against HIV infection following sexual exposure does not lead to increases in high-risk behavior. Aids 18(5): 787-792, 2004

Can emergency departments fulfil BASHH recommendations for 24-hour access to HIV postexposure prophylaxis following sexual exposure?. International Journal of Std and Aids 23(1): 75-76, 2012

Cost-effectiveness of postexposure prophylaxis after sexual or injection-drug exposure to human immunodeficiency virus. Archives of Internal Medicine 164(1): 46-54, 2004

Increasing rates of reported chemsex/sexualised recreational drug use in men who have sex with men attending for postexposure prophylaxis for sexual exposure. Sexually Transmitted Infections 93(1): 31, 2017

Cost-effectiveness of HIV postexposure prophylaxis following sexual or injection drug exposure in 96 metropolitan areas in the United States. Aids 18(15): 2065-2073, 2004

Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: the San Francisco PEP Study. Journal of Infectious Diseases 183(5): 707-714, 2001